Clinical trials: Recurrent Malignant Brain Neoplasm
Brain Tumors, Osteoporosis
Zoledronate in Preventing Osteoporosis in Patients With Primary Malignant Glioma
RATIONALE: Zoledronate may prevent bone loss in patients with primary malignant glioma. PURPOSE: This phase II trial is studying how well zoledronate works in preventing osteoporosis in patients with primary malignant glioma.
- Conditions
- Brain Tumors, Osteoporosis, Central Nervous System(CNS)Malignancies
- Trial name
- NCT00301873
- Testing
- IV Zometa
- Where
- United States
- Volunteers
- 60 people
- Sponsor
- Duke University
Brain and Central Nervous System Tumors
Temozolomide + Everolimus in Newly Diagnosed, Recurrent, or Progressive Malignant Glioblastoma Multiforme
RATIONALE: Drugs used in chemotherapy, such as temozolomide, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing.
- Trial name
- NCT00387400
- Testing
- everolimus, temozolomide, microarray analysis
- Where
- 9 sites in Canada
- Volunteers
- 32 people
- Sponsor
- NCIC Clinical Trials Group
Glioblastoma, Grade IV Astrocytoma
Convection-Enhanced Delivery (CED) of MDNA55 in Adults With Recurrent or Progressive Glioblastoma
This is a single-arm, open-label, multicenter study in approximately 52 adults with primary (de novo) GB that has recurred or progressed (first or second recurrence, including this recurrence) after treatment(s) including surgery…
- Conditions
- Glioblastoma, Grade IV Astrocytoma, Glioblastoma Multiforme, Grade IV Glioma
- Trial name
- NCT02858895
- Testing
- MDNA55
- Where
- 7 sites in United States
- Volunteers
- 47 people
- Sponsor
- Medicenna Therapeutics, Inc.
Brain Tumor, Brain Tumor, Recurrent
Monteris AutoLITT™ FIM Safety Trial for Recurrent/Progressive Brain Tumors
The main purpose of this study is to evaluate the safety and performance of the AutoLITT system for the treatment of recurrent/progressive glioblastoma multiforme tumors (GBM).
- Conditions
- Brain Tumor, Brain Tumor, Recurrent, Brain Neoplasm, Brain Cancer
- Trial name
- NCT00747253
- Testing
- AutoLITT system
- Where
- 2 sites in United States
- Volunteers
- 10 people
- Sponsor
- Monteris Medical
Cancer
Fentanyl Sublingual Spray in Treating Patients With Breakthrough Cancer Pain
This is a phase III, randomized, double-blind, placebo-controlled, multicenter study of the clinical response to fentanyl sublingual spray as a treatment for breakthrough cancer pain.
- Trial name
- NCT00538850
- Testing
- Fentanyl sublingual spray
- Where
- United States
- Volunteers
- 130 people
- Sponsor
- INSYS Therapeutics Inc
Adult Anaplastic Oligodendroglioma, Adult Mixed Glioma
Imatinib Mesylate in Treating Patients With Recurrent Brain Tumor
This phase I/II trial is studying the side effects and best dose of imatinib mesylate and to see how well it works in treating patients with a recurrent brain tumor that has not responded to previous surgery and radiation…
- Conditions
- Adult Anaplastic Oligodendroglioma, Adult Mixed Glioma, Adult Oligodendroglioma, Recurrent Adult Brain Neoplasm
- Trial name
- NCT00049127
- Testing
- Imatinib Mesylate, Laboratory Biomarker Analysis, Pharmacological Study
- Where
- 229 sites in United States
- Volunteers
- 64 people
- Sponsor
- Alliance for Clinical Trials in Oncology
Glioblastoma, Glioblastoma Multiforme
Trial of Niraparib in Participants With Newly-diagnosed Glioblastoma and Recurrent Glioma
This is an open-label, multi-center Phase 0 study with an expansion phase that will enroll up to 24 participants with newly-diagnosed glioblastoma and up to 18 recurrent glioma participants with IDH mutation and ATRX loss.
- Conditions
- Glioblastoma, Glioblastoma Multiforme, Glioma, GBM
- Trial name
- NCT05076513
- Testing
- Niraparib, Radiation therapy
- Where
- United States
- Volunteers
- 42 people
- Sponsor
- Nader Sanai
Brain Tumor, Glioblastoma
Suberoylanilide Hydroxamic Acid (SAHA), Bevacizumab, Daily Temozolomide for Recurrent Malignant Gliomas
This is a Phase I/II open-label, single-arm study among recurrent malignant glioma patients. Patients will be treated with Vorinostat in combination with Bevacizumab (BV) (10 mg/kg) and Temozolomide (T) (50 mg/m2/day) BV is…
- Trial name
- NCT00939991
- Testing
- Vorinostst/Bevacizumab/Temozolomide
- Where
- United States
- Volunteers
- 48 people
- Sponsor
- Katy Peters
Brain Neoplasms, Glioma
Bevacizumab and Irinotecan for Patients With Primary Brain Tumors and Progression After Standard Therapy
Irinotecan has demonstrated activity in malignant gliomas in multiple phase II studies. The activity is limited, with an approximately 15 % response rate and a progression-free survival of 3-5 months.
- Trial name
- NCT00463203
- Testing
- Bevacizumab, Irinotecan
- Where
- 3 sites in Denmark
- Volunteers
- 54 people
- Sponsor
- Copenhagen University Hospital, Rigshospitalet
Brain and Central Nervous System Tumors
Temozolomide in Treating Patients With Recurrent Glioblastoma Multiforme or Other Malignant Glioma
RATIONALE: Drugs used in chemotherapy, such as temozolomide, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing.
- Trial name
- NCT00498927
- Testing
- temozolomide, protein expression analysis, reverse transcriptase-polymerase chain reaction
- Where
- United States
- Volunteers
- 47 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Adult Anaplastic (Malignant) Meningioma, Adult Anaplastic Astrocytoma
Gadobutrol Versus Gadopentetate Dimeglumine or Gadobenate Dimeglumine Before DCE-MRI in Diagnosing Patients With Multiple Sclerosis, Grade II-IV Glioma, or Brain Metastases
This pilot clinical trial compares gadobutrol with standard of care contrast agents, gadopentetate dimeglumine or gadobenate dimeglumine, before dynamic contrast-enhanced (DCE)-magnetic resonance imaging (MRI) in diagnosing…
- Conditions
- Adult Anaplastic (Malignant) Meningioma, Adult Anaplastic Astrocytoma, Adult Anaplastic Ependymoma, Adult Anaplastic Oligodendroglioma
- Trial name
- NCT02967380
- Testing
- Dynamic Contrast-Enhanced Magnetic Resonance Imaging, Gadobenate Dimeglumine, Gadobutrol
- Where
- United States
- Volunteers
- 14 people
- Sponsor
- University of Southern California
Recurrent Childhood Medulloblastoma, Recurrent Ependymoma
Expanded Natural Killer Cell Infusion in Treating Younger Patients With Recurrent/Refractory Brain Tumors
This phase I trial studies the side effects and best dose of expanded natural killer cells in treating younger patients with brain tumors that have come back or do not respond to treatment.
- Conditions
- Recurrent Childhood Medulloblastoma, Recurrent Ependymoma, Recurrent Medulloblastoma
- Trial name
- NCT02271711
- Testing
- Laboratory Biomarker Analysis, Natural Killer Cell Therapy
- Where
- United States
- Volunteers
- 12 people
- Sponsor
- M.D. Anderson Cancer Center
Malignant Glioma, Recurrent Brain Neoplasm
18F-DOPA-PET in Planning Surgery in Patients With Gliomas
This pilot clinical trial studies fluorine F 18 fluorodopa (18F-DOPA)-positron emission tomography (PET) in planning surgery in patients with gliomas.
- Trial name
- NCT02020720
- Testing
- Biopsy, Computed Tomography, Diffusion Weighted Imaging
- Where
- United States
- Volunteers
- 72 people
- Sponsor
- Mayo Clinic
Brain and Central Nervous System Tumors
Combination Chemotherapy Followed by Peripheral Stem Cell Transplantation or Bone Marrow Transplantation in Treating Patients With Brain Cancer
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Peripheral stem cell transplantation or bone marrow transplantation may allow the doctor to give higher doses…
- Trial name
- NCT00025558
- Testing
- filgrastim, carboplatin, temozolomide
- Where
- 4 sites in United States, Australia
- Sponsor
- NYU Langone Health
Brain and Central Nervous System Tumors
Radiolabeled Monoclonal Antibody in Treating Patients With Glioblastoma Multiforme or Anaplastic Astrocytoma
RATIONALE: Radiolabeled monoclonal antibodies can locate tumor cells and deliver tumor-killing substances to them without harming normal cells. This may be an effective treatment for some types of brain tumors.
- Trial name
- NCT00004017
- Testing
- conventional surgery, iodine I 131 monoclonal antibody TNT-1/B
- Where
- 4 sites in United States
- Volunteers
- 60 people
- Sponsor
- Peregrine Pharmaceuticals
Brain and Central Nervous System Tumors
Immunotoxin Therapy in Treating Patients With Malignant Glioma
RATIONALE: Immunotoxins can locate tumor cells and kill them without harming normal cells. This may be an effective treatment for malignant glioma.
- Trial name
- NCT00006268
- Testing
- cintredekin besudotox, isolated perfusion, conventional surgery
- Where
- 11 sites in United States
- Sponsor
- New Approaches to Brain Tumor Therapy Consortium
Adult Anaplastic Astrocytoma, Adult Anaplastic Oligodendroglioma
VEGF Trap in Treating Patients With Recurrent Malignant Gliomas That Did Not Respond to Temozolomide
This phase II trial is studying how well VEGF Trap works in treating patients with recurrent malignant or anaplastic gliomas that did not respond to temozolomide.
- Conditions
- Adult Anaplastic Astrocytoma, Adult Anaplastic Oligodendroglioma, Adult Giant Cell Glioblastoma, Adult Gliosarcoma
- Trial name
- NCT00369590
- Testing
- ziv-aflibercept, pharmacological study, laboratory biomarker analysis
- Where
- 7 sites in United States
- Volunteers
- 58 people
- Sponsor
- National Cancer Institute (NCI)
KRAS Gene Mutation, Metastatic Malignant Neoplasm in the Brain
Regorafenib and Methotrexate in Treating Participants With Recurrent or Metastatic KRAS Mutated Non-Small Cell Lung Cancer
This phase II trial studies how well regorafenib works together with methotrexate in treating participants with metastatic non-squamous non-small cell lung cancer with tumors that harbor a KRAS mutation.
- Conditions
- KRAS Gene Mutation, Metastatic Malignant Neoplasm in the Brain, Recurrent Non-Small Cell Lung Carcinoma, Stage IV Non-Small Cell Lung Cancer AJCC v7
- Trial name
- NCT03520842
- Testing
- Methotrexate, Pharmacokinetic Study, Regorafenib
- Where
- United States
- Volunteers
- 22 people
- Sponsor
- Stanford University
Brain and Central Nervous System Tumors
Imaging Procedure Using ALA in Finding Residual Tumor in Grade IV Malignant Astrocytoma
RATIONALE: Imaging procedures that use aminolevulinic acid (ALA) may help find and diagnose residual tumor in participants with grade IV malignant astrocytoma who are undergoing surgery to remove the tumor.
- Trial name
- NCT00752323
- Testing
- aminolevulinic acid, Surgical Resection
- Where
- United States
- Volunteers
- 73 people
- Sponsor
- Andrew Sloan, MD
Glioblastoma, Gliosarcoma
Phase II Imatinib + Hydroxyurea in Treatment of Patients With Recurrent/Progressive Grade II Low-Grade Glioma (LGG)
Primary objective: To evaluate activity of imatinib mesylate and hydroxyurea among patients with progressive/recurrent grade II low-grade glioma (LGG) as measured by 12-month progression free survival Secondary objectives: To…
- Trial name
- NCT00615927
- Testing
- Imatinib Mesylate & Hydroxyurea
- Where
- United States
- Volunteers
- 64 people, healthy volunteers welcome
- Sponsor
- Duke University